© 2025 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Are Modafinil's Brain-Boosting Benefits Hype Or Science?

Nobody gets enough sleep these days and everyone needs to work harder. Sometimes coffee just doesn't seem like it's enough. Thus the temptation to apply pharmacology to thinking smarter, faster and longer.

One option is modafinil, a prescription drug approved by the Food and Drug Administration to treat narcolepsy. "I feel like a well-oiled machine 5 days a week on 5 hrs a night," one poster who uses modafinil writes on Reddit.

But there's no conclusive evidence that modafinil actually makes people think better.

The problem is, says Ahmed Mohamed, a psychologist at the University of Nottingham's campus in Malaysia, that "we don't really know how this drug is acting on the brain." In a small study published in the current issue of PLOS ONE, Mohammed found that rather than boosting cognition, the modafinil actually seemed to slow volunteers down.

While some small studies in rats and people have suggested that modafinil may improve memory, attention span or other aspects of cognition, other research has found no such link. One intriguing 2005 study suggested that it doesn't help people whose IQ is already high or even average.

The Food and Drug Administration first approved modafinil (brand name Provigil) for excessive sleepiness due to narcolepsy back in 1998. Since then, doctors increasingly have prescribed the drug off-label for everything from multiple sclerosis to depression.

For his study, Mohamed gathered 64 young, healthy volunteers and had half of them take modafinil, while the others took a placebo pill. He then had all the participants complete reading and sentence completion tests.

The two groups completed the tests equally well — but people in the group that got modafinil took slightly longer to respond to the questions. "Basically, this suggests that the drug might slow you down without making you smarter," Mohamed says.

The results, though preliminary, make sense, considering that modafinil is designed to promote wakefulness, says Dr. Larissa Mooney, an associate professor of psychiatry at UCLA. "It makes sense that people would feel more alert while taking it," she says. "But that doesn't necessarily mean that they're performing better."

It's unclear how many people use modafinil and other psychostimulant drugs like Adderall and Ritalin as a brain booster, though some public health officials and drug researchers say they are concerned.

Psychiatric patients are asking about the drug more often these days, Mooney says. "And we are getting an increase in requests for prescriptions to enhance performance."

She says she wouldn't recommend modafinil for that purpose, especially for young people, considering that researchers still aren't sure how it might affect brains that are still developing.

Side effects may also be a concern. In 2006, an FDA advisory committee recommended the agency not approve modafinil as a treatment for children with ADHD because it seemed to have caused a potentially fatal reaction called Stevens-Johnson syndrome in some patients.

"It's important to clarify that Provigil is indicated to improve wakefulness in adult patients," says Doris Saltkill, a spokesperson for Teva Pharmaceuticals, which manufactures modafinil under the brand name Provigil. The company doesn't recommend the drug for any other purpose, she says.

Given that there's no conclusive evidence that modafinil does anything to boost brain power, Mooney says, "Why not just have a cup of coffee?"

Copyright 2021 NPR. To see more, visit https://www.npr.org.

The independent journalism and non-commercial programming you rely on every day is in danger.

If you’re reading this, you believe in trusted journalism and in learning without paywalls. You value access to educational content kids love and enriching cultural programming.

Now all of that is at risk.

Federal funding for public media is under threat and if it goes, the impact to our communities will be devastating.

Together, we can defend it. It’s time to protect what matters.

Your voice has protected public media before. Now, it’s needed again. Learn how you can protect the news and programming you depend on.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

The independent journalism and non-commercial programming you rely on every day is in danger.

If you’re reading this, you believe in trusted journalism and in learning without paywalls. You value access to educational content kids love and enriching cultural programming.

Now all of that is at risk.

Federal funding for public media is under threat and if it goes, the impact to our communities will be devastating.

Together, we can defend it. It’s time to protect what matters.

Your voice has protected public media before. Now, it’s needed again. Learn how you can protect the news and programming you depend on.

Related Content